Source:http://linkedlifedata.com/resource/pubmed/id/14604548
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2003-11-7
|
pubmed:abstractText |
The CD69 antigen is the earliest activation marker expressed on leukocyte surfaces after stimulation and it has been correlated with disease state in a variety of inflammatory and autoimmune diseases. We were interested in the generation of a human monoclonal antibody (mAb) against the CD69 antigen. To do this, mice carrying human Ig transgenes (on an inactivated endogenous immunoglobulin H and Igkappa background) were immunized with rat cells transfected with the human CD69 molecule. From over 2000 hybridoma clones generated in different fusions, we were able to obtain a human monoclonal antibody, hAIM-29, which specifically recognizes human CD69 on the surface of activated-human leukocytes. We demonstrate that the antibody is specific for the human CD69 molecule, as shown by double staining with mouse anti-human CD69 antibodies, ELISA, immunoblot and immunoprecipitation studies. Results of additional experiments show that hAIM-29 activates intracellular calcium influx without Ig cross-linking and enhances phorbol myristate acetate-induced cell proliferation in a manner similar to other mouse anti-CD69 antibodies. This report is the first to describe the isolation and characterization of a novel human mAb, hAIM-29, which may have therapeutic potential in diseases associated with the presence of activated cells expressing CD69 antigen.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD69 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins, C-Type
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0022-1759
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
282
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
147-58
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:14604548-Animals,
pubmed-meshheading:14604548-Antibodies, Monoclonal,
pubmed-meshheading:14604548-Antigens, CD,
pubmed-meshheading:14604548-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:14604548-Calcium,
pubmed-meshheading:14604548-Cell Line, Tumor,
pubmed-meshheading:14604548-Humans,
pubmed-meshheading:14604548-Lectins, C-Type,
pubmed-meshheading:14604548-Lymphocyte Activation,
pubmed-meshheading:14604548-Mice,
pubmed-meshheading:14604548-Mice, Transgenic,
pubmed-meshheading:14604548-Rats
|
pubmed:year |
2003
|
pubmed:articleTitle |
The use of transgenic mice for the production of a human monoclonal antibody specific for human CD69 antigen.
|
pubmed:affiliation |
Area de Inmunología, Facultad de Ciencias, Universidad de Vigo, Lagoas-Marcosende s/n 36200 Vigo, Pontevedra, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|